Qiang Ruan1,2, Degang Ding3, Bin Wang4, Chaohong He5, Xuequn Ren6, Zhenhua Feng7, Zhigang Pang8, Jin Wang1, Xiangliang Zhang1, Hongsheng Tang1, Jiahong Wang1, Qingjun He1, Ziying Lei1, Quanxing Liao1, Jiali Luo1, Shuzhong Cui1. 1. Department of Abdominal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. 2. The First Affiliated Hospital of Jinan University, the First Clinical Medical College of Jinan University, Guangzhou 510630, China. 3. Department of Urinary Surgery, Henan Provincial People's Hospital, Zhengzhou 450003, China. 4. Department of Urinary Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. 5. Department of Urinary Surgery, Henan Cancer Hospital, Zhengzhou 450008, China. 6. Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng 475000, China. 7. Department of Urinary Surgery, Gaozhou People's Hospital, Maoming 525200, China. 8. Department of General Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.
Abstract
Objective: To compare the efficacy and safety of hyperthermic intravesical chemotherapy (HIVEC) and intravesical chemotherapy (IVEC) in patients with intermediate and high risk nonmuscle-invasive bladder cancer (NMIBC) after transurethral resection. Methods: We included 560 patients diagnosed with primary or recurrent NMIBC between April 2009 and December 2015 at 1 of 6 tertiary centers. We matched 364 intermediate or high risk cases and divided them into 2 groups: the HIVEC+IVEC group [chemohyperthermia (CHT) composed of 3 consecutive sessions followed by intravesical instillation without hyperthermia] and the IVEC group (intravesical instillation without hyperthermia). The data were recorded in the database. The primary endpoint was 2-year recurrence-free survival (RFS) in all NMIBC patients (n = 364), whereas the secondary endpoints were the assessment of radical cystectomy (RC) and 5-year overall survival (OS). Results: There was a significant difference in the 2-year RFS between the two groups in all patients (n = 364; HIVEC+IVEC: 82.42% vs. IVEC: 74.18%, P = 0.038). Compared with the IVEC group, the HIVEC+IVEC group had a lower incidence of RC (P = 0.0274). However, the 5-year OS was the same between the 2 groups (P = 0.1434). Adverse events (AEs) occurred in 32.7% of all patients, but none of the events was serious (grades 3-4). No difference in the incidence or severity of AEs between each treatment modality was observed. Conclusions: This retrospective study showed that HIVEC+IVEC had a higher 2-year RFS and a lower incidence of RC than IVEC therapy in intermediate and high risk NMIBC patients. Both treatments were well-tolerated in a similar manner. Copyright:
Objective: To compare the efficacy and safety of hyperthermic intravesical chemotherapy (HIVEC) and intravesical chemotherapy (IVEC) in patients with intermediate and high risk nonmuscle-invasive bladder cancer (NMIBC) after transurethral resection. Methods: We included 560 patients diagnosed with primary or recurrent NMIBC between April 2009 and December 2015 at 1 of 6 tertiary centers. We matched 364 intermediate or high risk cases and divided them into 2 groups: the HIVEC+IVEC group [chemohyperthermia (CHT) composed of 3 consecutive sessions followed by intravesical instillation without hyperthermia] and the IVEC group (intravesical instillation without hyperthermia). The data were recorded in the database. The primary endpoint was 2-year recurrence-free survival (RFS) in all NMIBC patients (n = 364), whereas the secondary endpoints were the assessment of radical cystectomy (RC) and 5-year overall survival (OS). Results: There was a significant difference in the 2-year RFS between the two groups in all patients (n = 364; HIVEC+IVEC: 82.42% vs. IVEC: 74.18%, P = 0.038). Compared with the IVEC group, the HIVEC+IVEC group had a lower incidence of RC (P = 0.0274). However, the 5-year OS was the same between the 2 groups (P = 0.1434). Adverse events (AEs) occurred in 32.7% of all patients, but none of the events was serious (grades 3-4). No difference in the incidence or severity of AEs between each treatment modality was observed. Conclusions: This retrospective study showed that HIVEC+IVEC had a higher 2-year RFS and a lower incidence of RC than IVEC therapy in intermediate and high risk NMIBC patients. Both treatments were well-tolerated in a similar manner. Copyright:
Authors: Morgan Rouprêt; Marko Babjuk; Eva Compérat; Richard Zigeuner; Richard Sylvester; Max Burger; Nigel Cowan; Andreas Böhle; Bas W G Van Rhijn; Eero Kaasinen; Joan Palou; Shahrokh F Shariat Journal: Eur Urol Date: 2013-03-19 Impact factor: 20.096
Authors: Samantha Cambier; Richard J Sylvester; Laurence Collette; Paolo Gontero; Maurizio A Brausi; George van Andel; Wim J Kirkels; Fernando Calais Da Silva; Willem Oosterlinck; Stephen Prescott; Ziya Kirkali; Philip H Powell; Theo M de Reijke; Levent Turkeri; Sandra Collette; Jorg Oddens Journal: Eur Urol Date: 2015-07-23 Impact factor: 20.096
Authors: Jesus Fernandez-Gomez; Rosario Madero; Eduardo Solsona; Miguel Unda; Luis Martinez-Piñeiro; Marcelino Gonzalez; Jose Portillo; Antonio Ojea; Carlos Pertusa; Jesus Rodriguez-Molina; Jose Emilio Camacho; Mariano Rabadan; Ander Astobieta; Manuel Montesinos; Santiago Isorna; Pedro Muntañola; Anabel Gimeno; Miguel Blas; Jose Antonio Martinez-Piñeiro Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: Tom J H Arends; Ofer Nativ; Massimo Maffezzini; Ottavio de Cobelli; Giorgio Canepa; Fabrizio Verweij; Boaz Moskovitz; Antoine G van der Heijden; J Alfred Witjes Journal: Eur Urol Date: 2016-01-20 Impact factor: 20.096
Authors: Karim Chamie; Mark S Litwin; Jeffrey C Bassett; Timothy J Daskivich; Julie Lai; Jan M Hanley; Badrinath R Konety; Christopher S Saigal Journal: Cancer Date: 2013-06-04 Impact factor: 6.860